Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone

Jazz Pharmaceuticals is acquiring Chimerix for $935 million in cash, or $8.55 per share123
The deal gives Jazz access to dordaviprone, a novel drug candidate for H3 K27M-mutant diffuse glioma, a rare brain tumor12
Dordaviprone has a PDUFA date of August 18, 2025 for potential FDA approval13
There are currently no FDA-approved therapies specifically for H3 K27M-mutant diffuse glioma2
The acquisition is expected to close in the second quarter of 202523
Dordaviprone has patent protection until 2037, with potential for extension34
If approved, dordaviprone may be eligible for a Rare Pediatric Disease Priority Review Voucher2
The deal strengthens Jazz's presence in rare oncology and adds a near-term commercial opportunity to its pipeline24

Sources:

1. https://www.fiercebiotech.com/biotech/jazz-hands-over-935m-buy-chimerix-near-approval-cancer-drug

2. https://ir.chimerix.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-chimerix-further-diversifying

3. https://www.globenewswire.com/news-release/2025/03/05/3037278/25619/en/Jazz-Pharmaceuticals-to-Acquire-Chimerix-Further-Diversifying-Oncology-Portfolio.html

4. https://www.biospace.com/business/jazz-expands-cancer-expertise-with-935m-chimerix-buy